Lilly finds impurity in compounded version of its weight-loss drug, warns of health risks

Core Viewpoint - Eli Lilly has identified an impurity in compounded versions of its weight-loss drug Zepbound, which could pose health risks to consumers, prompting a call for a nationwide recall of affected products [1][1][1] Group 1: Health Risks and Impurities - The impurity was found in all ten samples tested by Lilly, resulting from a chemical reaction between tirzepatide and vitamin B12 [1][1] - The long-term effects of this impurity on human health, including its interaction with GLP-1 and GIP receptors, remain unknown [1][1] - Lilly's chief medical officer emphasized that adding reactive substances like vitamin B12 without clinical testing introduces additional unknown risks [1][1] Group 2: Legal and Regulatory Actions - Lilly has taken legal action against compounders and wellness centers for marketing illegal copies of Zepbound and its diabetes drug Mounjaro [1][1] - The FDA has issued warning letters to 30 telehealth companies for making misleading claims about compounded weight-loss drugs [1][1] - The FDA has also threatened action against illegal copycat drugs, highlighting the regulatory scrutiny in the compounded drug market [1][1]